Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Eva Nozik to Rats, Sprague-Dawley

This is a "connection" page, showing publications Eva Nozik has written about Rats, Sprague-Dawley.

 
Connection Strength
 
 
 
0.279
 
  1. Nahar K, Absar S, Gupta N, Kotamraju VR, McMurtry IF, Oka M, Komatsu M, Nozik-Grayck E, Ahsan F. Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension. Mol Pharm. 2014 Dec 01; 11(12):4374-84.
    View in: PubMed
    Score: 0.083
  2. Rashid J, Nozik-Grayck E, McMurtry IF, Stenmark KR, Ahsan F. Inhaled combination of sildenafil and rosiglitazone improves pulmonary hemodynamics, cardiac function, and arterial remodeling. Am J Physiol Lung Cell Mol Physiol. 2019 01 01; 316(1):L119-L130.
    View in: PubMed
    Score: 0.027
  3. Rashid J, Alobaida A, Al-Hilal TA, Hammouda S, McMurtry IF, Nozik-Grayck E, Stenmark KR, Ahsan F. Repurposing rosiglitazone, a PPAR-? agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH. J Control Release. 2018 06 28; 280:113-123.
    View in: PubMed
    Score: 0.026
  4. Gupta N, Rashid J, Nozik-Grayck E, McMurtry IF, Stenmark KR, Ahsan F. Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency. Mol Pharm. 2017 03 06; 14(3):830-841.
    View in: PubMed
    Score: 0.024
  5. Rashid J, Patel B, Nozik-Grayck E, McMurtry IF, Stenmark KR, Ahsan F. Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH). J Control Release. 2017 03 28; 250:96-106.
    View in: PubMed
    Score: 0.024
  6. Irwin DC, Baek JH, Hassell K, Nuss R, Eigenberger P, Lisk C, Loomis Z, Maltzahn J, Stenmark KR, Nozik-Grayck E, Buehler PW. Hemoglobin-induced lung vascular oxidation, inflammation, and remodeling contribute to the progression of hypoxic pulmonary hypertension and is attenuated in rats with repeated-dose haptoglobin administration. Free Radic Biol Med. 2015 May; 82:50-62.
    View in: PubMed
    Score: 0.021
  7. Gupta V, Gupta N, Shaik IH, Mehvar R, Nozik-Grayck E, McMurtry IF, Oka M, Komatsu M, Ahsan F. Inhaled PLGA particles of prostaglandin E1 ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency. Mol Pharm. 2013 May 06; 10(5):1655-67.
    View in: PubMed
    Score: 0.019
  8. Tang JR, Michaelis KA, Nozik-Grayck E, Seedorf GJ, Hartman-Filson M, Abman SH, Wright CJ. The NF-?B inhibitory proteins I?Ba and I?B? mediate disparate responses to inflammation in fetal pulmonary endothelial cells. J Immunol. 2013 Mar 15; 190(6):2913-23.
    View in: PubMed
    Score: 0.018
  9. Gupta V, Gupta N, Shaik IH, Mehvar R, McMurtry IF, Oka M, Nozik-Grayck E, Komatsu M, Ahsan F. Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. J Control Release. 2013 Apr 28; 167(2):189-99.
    View in: PubMed
    Score: 0.018
  10. Buehler PW, Baek JH, Lisk C, Connor I, Sullivan T, Kominsky D, Majka S, Stenmark KR, Nozik-Grayck E, Bonaventura J, Irwin DC. Free hemoglobin induction of pulmonary vascular disease: evidence for an inflammatory mechanism. Am J Physiol Lung Cell Mol Physiol. 2012 Aug 15; 303(4):L312-26.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)